Nurix therapeutics advances promising targeted protein modulation pipeline and outlines 2023 strategic priorities

Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its deligase platform

NRIX Ratings Summary

NRIX Quant Ranking